Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Deliniasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Proteomic Profiling to Identify Prognostic Biomarkers in Heart Failure. P.A. SCOTT, B. ZEIDAN, L.L. NG, M. ZEB, J.A. ROSENGARTEN, S. GARBUS, N.P. CURZEN, J.M. MORGAN, P.A. TOWNSEND (Southampton; Leicester, UK; Athens, Greece)

Diverging In Vitro Antibody Isotype Switching Preference in B-Lymphocytes from C57BL/6 and FVB Mice. A.G. PUTHIYAVEETIL, B. OKYERE, C.M. REILLY, D. CAUDELL (Blacksburg, VA, USA)

The Zebrafish - Danio rerio – Is a Useful Model for Measuring the Effects of Small-molecule Mitigators of Late Effects of Ionizing Irradiation. M.W. EPPERLY, N. BAHARY, M. QUADER, V. DEWALD, J.S. GREENBERGER (Pittsburgh, PA, USA)

Breast Cancer: Mechanisms Involved in Action of Phytoestrogens and Epigenetic Changes. A. DAGDEMIR, J. DURIF, M. NGOLLO, Y.-J. BIGNON, D. BERNARD-GALLON (Clermont-Ferrand, France)

Positron-emission Tomography (PET) Imaging Agents for Diagnosis of Human Prostate Cancer: Agonist vs. Antagonist Ligands. P.K. NANDA, B.E. WIENHOFF, T.L. ROLD, G.L. SIECKMAN, T.J. HOFFMAN, B.E. ROGERS, C.J. SMITH (Columbia; St. Louis, MO, USA)

In Vivo Models for Defining Molecular Subtypes of the Primitive Neuroectodermal Tumor Genome: Current Challenges and Solutions. J.D. LARSON, D.A. LARGAESPA (Minneapolis, MN, USA)

Effects of Minocycline on Hematopoietic Recovery After Whole-body Irradiation. S. MEHROTRA, M.J. PECAUT, D.S. GRIDLEY (Loma Linda, CA, USA)

Sequential Changes in the Expression of Wnt- and Notch-related Genes in the Vagina and Uterus of Ovariectomized Mice after Estrogen Exposure. T. NAKAMURA, S. MIYAGAWA, Y. KATSU, T. SATO, T. IGUCHI, Y. OHTA (Yamagata; Okazaki; Sapporo; Yokohama; Tottori, Japan)

Catecholamines Reduce Dose-dependent Oedema Formation and Inflammatory Reaction in an Isolated Rat Lung Model. C. DACHO, A. DACHO, A. GEISSLER, C. HAUSER, K. NOWAK, G. BECK (Heidelberg; Essen; Wiesbaden, Germany)

Biocompatibility of Membranes with Unrestricted Somatic Stem Cells. C. NAUJOKS, F.P. VON BECK, F. LANGEBAECHER, M. HENTSCHEL, M. BORGGREVE, D. HAGH, J. SAUR (Mannheim, Germany)

Acclimatization of Mice to Different Cage Types and Social Groupings with Respect to Fecal Secretion of IgA and Corticosterone Metabolites. C.J. BUNDGAARD, O. KALLIO, K.S. ABELSON, J. HAU (Copenhagen, Denmark)

Exploring Anticarcinogenic Agents in a Rat Hepatocarcinogenesis Model – Focus on Selenium and Statins. L. BJÖRKHEM-BERGMAN, L. ERSTRÖM, L.C. ERIKSSON (Stockholm, Sweden)


Amino Acid Chloramine Damage to Proliferating Cell Nuclear Antigen in Mammalian Cells. S.A. SALAMA, R.M. SNAPKA (Columbus, OH, USA; Cairo, Egypt)

The Effect of Insulin-like Growth Factor II in the Regulation of Tumour Cell Growth In Vitro and Tumourigenesis In Vivo. M. HALJE, M. NORDIN, D. BERGMAN, W. ENGSTRÖM (Uppsala, Sweden)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST
Subscription Order Form 2014

☐ Please enter a Subscription to ANTICANCER RESEARCH Volume 34 (2014).
   Annual subscription rates (2013): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;
   Prices include rapid delivery and insurance.
   2014 online subscriptions include free online access to vol. 24 (2004) - 33 (2013).
☐ Please send me the following previous volumes (1-33) at 50% discount on the above rates.
☐ Payment is enclosed. ☐ Please invoice.
   Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).
☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ..................................................................................................................................................
Tel: .......................................................................................................................... .............................................................
Fax: ....................................................................................................................... e-mail: ............................................
Signature:............................................................................................................... Date:..................................................

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2014 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2014 on a basis of priority and availability. Effective from January to December 2014).

● Included in Pubmed, Current Contents and all abstracting and indexing services
● Online with Stanford University HighWire Press
● Open access articles

Please complete and send this order form to:
ANTICANCER RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2014

☐ I am one of the authors of the article published in Anticancer Research Vol........, pp. ........, year ........
☐ Please enter my personal subscription to Anticancer Research 2014 (Volume 34) at the special Author’s rate of Euro 390.00 (print or online).
☐ Please send me previous Volume No(s) ............ at Euro 195.00 (print) per volume.
☐ Please enter my personal combined 2014 subscription to Anticancer Research (Volume 34) and IN VIVO (Volume 28) at Euro 560.00 (print or online).
☐ My payment is enclosed.
☐ Please send me an invoice.
   Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address: ..................................................................................................................................................
Tel-Fax: ....................................................................................................................... e-mail: ............................................
Date and signature: ...........................................................................................................................
A Selection of Recent Papers

Metastatic Biomarker Discovery Through Proteomics. L.T. BRINTON, T.A. BRENTNALL, J.A. SMITH, K.A. KELLY (Charlottesville, VA; Seattle, WA, USA)


Review: Breast Cancer and Metastasis: On the Way Toward Individualized Therapy. A.P. TRAPÊ, A.M. GONZALEZ-ANGULO (Houston, TX, USA)

In Silico Functional Profiling of Individual Prostate Cancer Tumors: Many Genes, Few Functions. I.P. GORLOV, J. BYUN, C.J. LOGOTHETIS (Houston, TX, USA)

Expression of Signal-induced Proliferation-associated Gene 1 (SIPA1), a RapGTPase-activating Protein, Is Increased in Colorectal Cancer and Has Diverse Effects on Functions of Colorectal Cancer Cells. K. JI, L. YE, A.-M. TOMS, R. HARGEST, T.A. MARTIN, F. RUGE, J. JI, W.G. JIANG (Cardiff; UK; Beijing, PR China)

Single Nucleotide Polymorphisms of Genes for EGF, TGF-β and TNF-α in Patients with Pancreatic Carcinoma. L. ZHANG, G. WU, F. HERRLE, M. NIEDERGETHLMANN, M. KESE (Frankfurt; Heidelberg, Germany; Xiamen, P.R. China)

Diagnostic MicroRNA Markers to Screen for Sporadic Human Colon Cancer in Blood. F.E. AHMED, N..C. AMED, P.W. VOS, C. BONNERUP, J.N. ATKINS, M. CASEY, G.J. NUOVO, W. NAZIRI, J.E. WILEY, R.R. ALLISON (Greenville, Goldsboro, NC; Columbus, OH, USA)

MGMT Hypermethylation and MDR System in Glioblastoma Cancer Stem Cells. V. CALDERA, M. MELLAI, L. ANNOVAZZI, O. MONZEGLIO, A. PIAZZI, D. SCHIFFER (Pavia; Novara, Italy)

20-HETE-producing Enzymes Are Up-regulated in Human Cancers. A. ALEXANIAN, B. MILLER, R.J. ROMAN, A. SOROKIN (Milwaukee, WI; Jackson, MS, USA)

Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes are Evolutionarily Conserved. L.M. PAVA, D.T. MORTON, R. CHEN, G. BLANCK (Tampa, FL, USA)
Correlation of Wilms’ Tumor 1 Isoforms with HER2 and ER-α and its Oncogenic Role in Breast Cancer. T. NASOMYON, S. SAMPHAO, S. SANGKHATHAT, S. MAHATTANOBON, P. GRAIDIST (Hat-Yai, Songkhla, Thailand) ................................................................. 1333

Effect of Cytochrome C and Vitamin C on the Survival of MCF-7 Cancer Cells Under γ-Ray Treatment. G. WALDER, N. GETOFF (Vienna, Austria) ........................................................................................................... 1343

Human Chorionic Gonadotropin Suppresses Human Breast Cancer Cell Growth Directly via p53-mediated Mitochondrial Apoptotic Pathway and Indirectly via Ovarian Steroid Secretion. T. YURI, Y. KINOSHITA, Y. EMOTO, K. YOSHIZAWA, A. TSUBURA (Hirakata, Osaka, Japan) ...................................................... 1347


In Vitro and In Vivo Efficacy of a Novel Quinuclidinone Derivative Against Breast Cancer. A. MALIKI, E.S. EL ASHRY (Doha, Qatar; Alexandria, Egypt) ........................................................................................................ 1367


Tumor Suppressor PTEN in Breast Cancer: Heterozygosity, Mutations and Protein Expression. P. KECHAGIOGLOU, R.M. PAPI, X. PROVATOPOULOU, E. KALOGERA, E. PAPADIMITRIOU, P. GRIGOROPOULOS, A. NONNI, G. ZOGRAFOS, D.A. KYRIAKIDIS, A. GOUNARIS (Thessaloniki; Athens, Greece) ........................................................................ 1387


Prolyl-isomerase Pin1 Impairs Trastuzumab Sensitivity by Up-regulating Fatty Acid Synthase Expression. H.J. YUN, J.Y. KIM, G. KIM, H.S. CHOI (Gwangju, Republic of Korea) .......................................................... 1409

Expression of Breast Cancer Metastasis Suppressor-1, BRMS-1, in Human Breast Cancer and the Biological Impact of BRMS-1 on the Migration of Breast Cancer Cells. Y. ZHANG, L. YE, Y. TAN, P. SUN, K. JI, W.G. JIANG (Cardiff, UK; Jinan; Zibo City, Shandong Province, China) ............................................................................. 1417

Co-expression of Stem Cell Markers ALDH1 and CD44 in Non-malignant and Neoplastic Lesions of the Breast. A. DA CRUZ PAULA, O. MARQUES, A.M. ROSA, M.F. FARIA, A. RÉMA, C. LOPES (Porto, Portugal) ........................................................................................................ 1427

Hormone Receptors and HER2 Expression in Primary Breast Carcinoma and Corresponding Lymph Node Metastasis: Do we Need Both? M. RAICA, A.M. CÎMPEAN, R.A. CEAUŞU, V. FULGA, C. NICA, L. RUDICO, L. SAPTEFRATI (Timisoara, Romania; Chișinău, Republic of Moldavia) ........................................................................................................ 1435


Erratum ........................................................................................................................................... 1457


Bisphosphonate-related Atypical Femoral Fracture with Bone Metastasis of Breast Cancer: Case Report and Review. K. HAYASHI, M. AONO, K. SHINTANI, K. KAZUKI (Osaka, Japan) ........................................................................................................... 1245

Nuclear Survivin Expression in Stromal Cells of Phyllodes Tumors and Fibroadenomas of the Breast. H. HIRANO, K. MATSUSHITA, A. OKIMURA, T. YOSHIDA, T. KIZAKI, T. ITO (Himeji; Hyogo; Sanda, Hyogo; Toyonaka, Osaka, Japan) ........................................................................................................... 1251

Impact of the Prognostic Value of Vascular Invasion, but Not Lymphatic Invasion, of the Primary Tumor in Patients with Breast Cancer. T. FUJII, R. YAJIMA, T. HIRAKATA, T. MIYAMOTO, T. FUJISAWA, S. TSUTSUMI, Y. YNAGITA, M. IIJIMA, H. KUWANO (Maebashi; Ota, Gunma, Japan) ........................................................................................................... 1255

Overexpression of Androgen Receptor and Forkhead-box A1 Protein in Apocrine Breast Carcinoma. M. SASAHARA, A. MATSUI, Y. ICHIMURA, Y. HIRAKATA, Y. MURATA, E. MARUI (Tokyo, Japan) ........................................................................................................... 1261

Contribution of Emotional Distance and Reserve in Patient–Physician Communication in Healthy Study Patients, and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case–Control Study in Finland. M. ESKELINEN, P. OLLONEN (Kuopio, Finland) ........................................................................................................... 1269

First-line Bevacizumab–Paclitaxel in 220 Patients with Metastatic Breast Cancer: Results from the AVAREG Study. M. DANK, L. BUDI, B. PIKO, L. MANGEL, J. ERFAN, J. CSEH, A. RUZSA, L. LANDHERR (Budapest; Miskolc; Gyula; Pécs; Nyíregyháza; Székesfehérvár; Zalaegerszeg, Hungary) ........................................................................................................... 1275

Surgery for Breast Cancer Liver Metastases – Factors Determining Results. V. TRESKA, M. CERNA, V. LISKA, I. TRESKOVA, A. NARSANSKA, J. BRUHA (Pilsen, Czech Republic) ........................................................................................................... 1281

Therapeutic Activity of Testosterone in Metastatic Breast Cancer. C. BONI, M. PAGANO, M. PANEBIANCO, A. BOLOGNA, N.M.A. SIERRA, R. GNONI, D. FORMISANO, G. BISAGNI (Reggio Emilia, Italy) ........................................................................................................... 1287


T1-T2 Breast Cancer with Nodal Metastasis: Characteristics of pN2 or Higher Disease Compared to pN1 Disease. M.Y. KIM, N. CHOI, J.-H. YANG, Y.B. YOO, K.S. PARK, W.S. KIM (Seoul, Republic of Korea) ........................................................................................................... 1295

Identification of Patients with Node-negative, Triple-negative Breast Cancer who Benefit from Adjuvant Cyclophosphamide, Methotrexate, and 5-Fluorouracil Chemotherapy. C.-E. WU, S.-C. CHEN, Y.-C. HSUEH, H.-K. Chang (Taoyuan, Taiwan, ROC) ........................................................................................................... 1301

Experimental Studies

Cell Identity Disruption in Breast Cancer Precursors. D. CORADINI, P. BORACCHI, S. ORIANA, E. BIGANZOLI, F. AMBROGI (Milan, Italy) ........................................................................................................... 1307

Propofol and Bupivacaine in Breast Cancer Cell Function In Vitro – Role of the NET1 Gene. P. ECIMOVIC, D. MURRAY, P. DORAN, D.J. BUGGY (Dublin, Ireland; Cleveland, OH, USA) ........................................................................................................... 1321

Contents continued on the preceding page
Endothelial Dysfunction as a Determinant of Trastuzumab-mediated Cardiotoxicity in Patients with Breast Cancer. A. SANDOO, G.D. KITAS, A.R. CARMICHAEL (Dudley, West Midlands, UK)................................. 1147

**Clinical Studies**


Meta-analysis of Vitamin D Sufficiency for Improving Survival of Patients with Breast Cancer. S.B. MOHR, E.D. GORHAM, J. KIM, H. HOFFLICH, C.F. GARLAND (San Diego; La Jolla, CA, USA) .................. 1163

Plasma Free Serotonin as a Marker for Early Detection of Breast Cancer Recurrence. A. FRÖBE, L. ČIČIN-ŠAÍN, G. JONES, Ž. SOLDIČ, J. LUKAČ, A. BOLANČA, Z. KUSIĆ (Zagreb, Croatia; Mississauga, ON, Canada) ........................................ 1167

Morphometric and Fractal Dimension Analysis Identifies Early Neoplastic Changes in Mammary Epithelium of MMTV-cNeu Mice. J.W. FUSELER, J.P. ROBICHAUX, H.I. ATIYAH, A.F. RAMSDELL (Columbia; Charleston, SC, USA) ................................. 1171

Pemetrexed-induced Radiation Recall Dermatitis of the Breast. S. BOESMANS, L. DECOSTER, D. SCHALLIER (Brussels, Belgium) ........................................................................................................ 1179

Characteristics Associated with Upgrading to Invasiveness After Surgery of a DCIS Diagnosed Using Percutaneous Biopsy. J.-C. HOGUE, L. MORAIS, L. PROVENCHER, Č. DESBIENS, B. POIRIER, É. POIRIER, S. JACOB, C. DIO RIO (Quebec City, QC, Canada) ........................................................... 1183

Experiences of Breast Cancer Survivors Participating in a Tailored Exercise Intervention –A Qualitative Study. M.-L. LUOMA, L. HAKAMIES-BLOMQVIST, C. BLOMQVIST, R. NIKANDER, M. GUSTAVSSON-LILIUS, T. SAARTO (Helsinki; Tampere, Finland) ....................................................................... 1193

Quality of Life of Recently Treated Patients with Breast Cancer. H. PENTTINEN, M. RAUTALIN, R. ROINE, T. JAHKOLA, P.-L. KELLOKUMPU-LEHTINEN, R. HUOVINEN, H. KAUTIAINEN, S. JÄRVENPÄÄ, L. HAKAMIES-BLOMQVIST, C. BLOMQVIST, T. SAARTO (Helsinki; Tampere; Turku; Jyväskylä; Äänekoski, Finland) ................................................................. 1201

Human Epidermal Growth Factor Receptor-2 Positivity Predicts Loco-regional Recurrence in Patients with T1-T2 Breast Cancer. G.A. CEFARO, D. GENOVESI, M. TRIGNANI, M. DI NICOLA (Chieti, Italy) .... 1207


Accuracy of Mammography, Digital Breast Tomosynthesis, Ultrasound and MR Imaging in Preoperative Assessment of Breast Cancer. G. MARISCOTTI, N. HOUSSAMI, M. DURANDO, L. BERGAMASCO, P.P. CAMPANINO, C. RUGGIERI, E. REGINI, A. LUPARIA, R. BUSSONE, A. SAPINO, P. FONIO, G. GANDINI (Turin, Italy; Sydney, NSW, Australia; Brussels, Belgium) .......................................................... 1219

Low Protein Expression of MET in ER-positive and HER2-positive Breast Cancer. F. ZAGOURI, A. BRANDSTETTER, D. MOUS SSIOLIS, D. CHRYSIKOS, C. DIMITRAKAKIS, A. TSIGGINOU, S. MARINOPoulos, G.C. ZOGRAFOS, T.N. SERGENTANIS, M.-A. DIMOPoulos, M. FILIPITS (Vienna, Austria; Athens, Greece) ............................................................................................................... 1227

*Contents continued on the preceding page*